Ovid Therapeutics 
Welcome,         Profile    Billing    Logout  
 1 Product   1 Disease  1 Product   1 Trial   186 News 
12 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
gaboxadol (OV101) / Ovid Therapeutics, Healx
NCT06334419: Placebo-Controlled, Single-Dose Challenge Study of Gaboxadol in Adult Males With Fragile X Syndrome (FXS)

Recruiting
2
10
US
Gaboxadol, Placebo
Craig Erickson, Healx Limited
Fragile X Syndrome
09/24
09/24
soticlestat (TAK-935) / Takeda
SKYWAY, NCT04938427 / 2021-002481-40: A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults With Lennox-Gastaut Syndrome

Completed
3
270
Europe, Canada, Japan, US, RoW
Placebo, Soticlestat, TAK-935
Takeda
Lennox Gastaut Syndrome (LGS)
01/24
01/24
SKYLINE, NCT04940624 / 2021-002480-22: A Study of Soticlestat as an Add-on Therapy in Children and Young Adults With Dravet Syndrome

Completed
3
144
Europe, Canada, Japan, US, RoW
Soticlestat, TAK-935, Placebo
Takeda
Dravet Syndrome (DS)
04/24
04/24
TAK-935-3004, NCT06422377: A Study Evaluating Soticlestat in Participants With Dravet Syndrome or Lennox-Gastaut Syndrome Who Have Been Exposed to Fenfluramine

Terminated
3
1
Europe
Soticlestat, TAK-935
Takeda
Dravet Syndrome (DS), Lennox-Gastaut Syndrome (LGS)
08/24
08/24
ENDYMION 2, NCT05163314 / 2021-002482-17: A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome

Active, not recruiting
3
400
Europe, Canada, Japan, US, RoW
Soticlestat, TAK-935
Takeda
Dravet Syndrome (DS), Lennox Gastaut Syndrome (LGS)
05/26
05/26
2018-002485-39: A PHASE 2, PROSPECTIVE, INTERVENTIONAL, OPEN-LABEL, MULTI-SITE, EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND TOLERABILITY OF TAK-935 AS ADJUNCTIVE THERAPY IN PATIENTS WITH RARE EPILEPSY Estudio de extensión de fase 2, prospectivo, intervencionista, abierto y multicéntrico para evaluar la seguridad y tolerabilidad a largo plazo de TAK-935 como tratamiento complementario en pacientes con epilepsia rara

Ongoing
2
176
Europe, RoW, Canada, US
TAK-935, TAK-935, Tablet
Ovid Therapeutics, Inc., Takeda Development Center Americas, Inc., Ovid Therapeutics, Inc., Takeda Development Center Americas, Inc., Takeda Development Center Americas, Inc
developmental and epileptic encephalopathies encefalopatías epilépticas y del desarrollo, developmental and epileptic encephalopathies encefalopatías epilépticas y del desarrollo, Diseases [C] - Nervous System Diseases [C10]
 
 
2018-002484-25: A phase 2, multicenter, randomized, double-blind, controlled with placebo, to obtaine efficacy , safety and tolerability information for TAK-935 as an adjuntive therapy in pediatric patinets ((aged ≥2 and ≤17 years) with developmental and/or epileptic encephlopathies (Dravet syndrome and Lennox Gastaut)

Not yet recruiting
2
126
Europe
TAK-935, Tablet
Takeda Development Center Americas, Inc., Takeda Development Center Americas, Inc.
Epileptic Encephalitis: Dravet and Lennox Gastuat syndrome (LGS), Epileptic Encephalitis: Dravet and Lennox Gastuat syndrome (LGS), Diseases [C] - Nervous System Diseases [C10]
 
 
2018-004750-21: Study of TAK-935 as an Adjunctive Therapy in Adult Subjects With Complex Regional Pain Syndrome

Not yet recruiting
2
24
Europe
TAK-935, TAK-935, Tablet
Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda, Millennium Pharmaceuticals
Complex Regional Pain Syndrome (CRPS), Complex Regional Pain Syndrome (CRPS), Diseases [C] - Nervous System Diseases [C10]
 
 
Endymion, NCT03635073 / 2018-002485-39: A Study of Soticlestat in Adults and Children With Rare Epilepsies

Active, not recruiting
2
156
Europe, Canada, US, RoW
Soticlestat, TAK-935
Takeda, Ovid Therapeutics, Inc., Takeda Development Center Americas, Inc., Takeda Development Center Americas, Inc
Epilepsy, Dravet Syndrome (DS), Lennox-Gastaut Syndrome (LGS)
05/26
05/26
NCT05602818: A Study of Soticlestat in Healthy Adult Nondependent Recreational Drug Users With Central Nervous System (CNS) Depressant Experience

Completed
1
100
US
Soticlestat 300 mg, Soticlestat 600 mg, Soticlestat 900 mg, Alprazolam, Placebo
Takeda
Healthy Volunteers
06/23
07/23
OV329 / Ovid Therapeutics
ACTRN12624000214538: An ascending, single and multiple dose(s), double-blind, randomized, placebo controlled study assessing the safety, tolerability, and pharmacokinetics of ov329 in healthy male and female participants

Recruiting
1
64
 
Ovid Therapeutics Australia Pty Ltd, Ovid Therapeutics Australia Pty Ltd
rare seizure disorders
 
 
OV350 / Ovid Therapeutics
ACTRN12625000428460: An Ascending, Single and Multiple Dose(s), Double-Blind, Randomized, Placebo Controlled Study Assessing the Safety, Tolerability, and Pharmacokinetics of Intravenous OV350 in Healthy Male and Female Participants

Recruiting
1
72
 
Ovid Therapeutics Australia Pty Ltd, Ovid Therapeutics Australia Pty Ltd
Parkinson's Disease
 
 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
gaboxadol (OV101) / Ovid Therapeutics, Healx
NCT06334419: Placebo-Controlled, Single-Dose Challenge Study of Gaboxadol in Adult Males With Fragile X Syndrome (FXS)

Recruiting
2
10
US
Gaboxadol, Placebo
Craig Erickson, Healx Limited
Fragile X Syndrome
09/24
09/24
soticlestat (TAK-935) / Takeda
SKYWAY, NCT04938427 / 2021-002481-40: A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults With Lennox-Gastaut Syndrome

Completed
3
270
Europe, Canada, Japan, US, RoW
Placebo, Soticlestat, TAK-935
Takeda
Lennox Gastaut Syndrome (LGS)
01/24
01/24
SKYLINE, NCT04940624 / 2021-002480-22: A Study of Soticlestat as an Add-on Therapy in Children and Young Adults With Dravet Syndrome

Completed
3
144
Europe, Canada, Japan, US, RoW
Soticlestat, TAK-935, Placebo
Takeda
Dravet Syndrome (DS)
04/24
04/24
TAK-935-3004, NCT06422377: A Study Evaluating Soticlestat in Participants With Dravet Syndrome or Lennox-Gastaut Syndrome Who Have Been Exposed to Fenfluramine

Terminated
3
1
Europe
Soticlestat, TAK-935
Takeda
Dravet Syndrome (DS), Lennox-Gastaut Syndrome (LGS)
08/24
08/24
ENDYMION 2, NCT05163314 / 2021-002482-17: A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome

Active, not recruiting
3
400
Europe, Canada, Japan, US, RoW
Soticlestat, TAK-935
Takeda
Dravet Syndrome (DS), Lennox Gastaut Syndrome (LGS)
05/26
05/26
2018-002485-39: A PHASE 2, PROSPECTIVE, INTERVENTIONAL, OPEN-LABEL, MULTI-SITE, EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND TOLERABILITY OF TAK-935 AS ADJUNCTIVE THERAPY IN PATIENTS WITH RARE EPILEPSY Estudio de extensión de fase 2, prospectivo, intervencionista, abierto y multicéntrico para evaluar la seguridad y tolerabilidad a largo plazo de TAK-935 como tratamiento complementario en pacientes con epilepsia rara

Ongoing
2
176
Europe, RoW, Canada, US
TAK-935, TAK-935, Tablet
Ovid Therapeutics, Inc., Takeda Development Center Americas, Inc., Ovid Therapeutics, Inc., Takeda Development Center Americas, Inc., Takeda Development Center Americas, Inc
developmental and epileptic encephalopathies encefalopatías epilépticas y del desarrollo, developmental and epileptic encephalopathies encefalopatías epilépticas y del desarrollo, Diseases [C] - Nervous System Diseases [C10]
 
 
2018-002484-25: A phase 2, multicenter, randomized, double-blind, controlled with placebo, to obtaine efficacy , safety and tolerability information for TAK-935 as an adjuntive therapy in pediatric patinets ((aged ≥2 and ≤17 years) with developmental and/or epileptic encephlopathies (Dravet syndrome and Lennox Gastaut)

Not yet recruiting
2
126
Europe
TAK-935, Tablet
Takeda Development Center Americas, Inc., Takeda Development Center Americas, Inc.
Epileptic Encephalitis: Dravet and Lennox Gastuat syndrome (LGS), Epileptic Encephalitis: Dravet and Lennox Gastuat syndrome (LGS), Diseases [C] - Nervous System Diseases [C10]
 
 
2018-004750-21: Study of TAK-935 as an Adjunctive Therapy in Adult Subjects With Complex Regional Pain Syndrome

Not yet recruiting
2
24
Europe
TAK-935, TAK-935, Tablet
Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda, Millennium Pharmaceuticals
Complex Regional Pain Syndrome (CRPS), Complex Regional Pain Syndrome (CRPS), Diseases [C] - Nervous System Diseases [C10]
 
 
Endymion, NCT03635073 / 2018-002485-39: A Study of Soticlestat in Adults and Children With Rare Epilepsies

Active, not recruiting
2
156
Europe, Canada, US, RoW
Soticlestat, TAK-935
Takeda, Ovid Therapeutics, Inc., Takeda Development Center Americas, Inc., Takeda Development Center Americas, Inc
Epilepsy, Dravet Syndrome (DS), Lennox-Gastaut Syndrome (LGS)
05/26
05/26
NCT05602818: A Study of Soticlestat in Healthy Adult Nondependent Recreational Drug Users With Central Nervous System (CNS) Depressant Experience

Completed
1
100
US
Soticlestat 300 mg, Soticlestat 600 mg, Soticlestat 900 mg, Alprazolam, Placebo
Takeda
Healthy Volunteers
06/23
07/23
OV329 / Ovid Therapeutics
ACTRN12624000214538: An ascending, single and multiple dose(s), double-blind, randomized, placebo controlled study assessing the safety, tolerability, and pharmacokinetics of ov329 in healthy male and female participants

Recruiting
1
64
 
Ovid Therapeutics Australia Pty Ltd, Ovid Therapeutics Australia Pty Ltd
rare seizure disorders
 
 
OV350 / Ovid Therapeutics
ACTRN12625000428460: An Ascending, Single and Multiple Dose(s), Double-Blind, Randomized, Placebo Controlled Study Assessing the Safety, Tolerability, and Pharmacokinetics of Intravenous OV350 in Healthy Male and Female Participants

Recruiting
1
72
 
Ovid Therapeutics Australia Pty Ltd, Ovid Therapeutics Australia Pty Ltd
Parkinson's Disease
 
 

Download Options